Linear and branched glyco-lipopeptide vaccines follow distinct cross-presentation pathways and generate different magnitudes of antitumor immunity

PLoS ONE

Volumn 5, Issue 6, 2010, Pages

  Renaudet, Olivier ^a,b   Dasgupta, Gargi ^a   Bettahi, Ilham ^a   Shi, Alda ^a   Nesburn, Anthony B ^a   Dumy, Pascal ^b   BenMohamed, Lbachir ^a,c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITÉ JOSEPH FOURIER   (France)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE; CARBOHYDRATE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPITOPE; GAMMA INTERFERON; GLYCOPEPTIDE; GLYCOPEPTIDOLIPID; HER2 GLYCOLIPOPEPTIDE 1 VACCINE; HER2 GLYCOLIPOPEPTIDE 2 VACCINE; HER2 GLYCOLIPOPEPTIDE VACCINE; IMMUNOGLOBULIN G; N ACETYLGALACTOSAMINE; PALMITIC ACID; PEPTIDE; PHOSPHATE BUFFERED SALINE; TOLL LIKE RECEPTOR 2; UNCLASSIFIED DRUG; CD4 ANTIGEN; CD8 ANTIGEN; GLYCOPROTEIN; LIPOPEPTIDE; SUBUNIT VACCINE;

AMINO TERMINAL SEQUENCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER INHIBITION; CARBOXY TERMINAL SEQUENCE; CD8+ T LYMPHOCYTE; CELL MATURATION; CELLULAR IMMUNITY; CONTROLLED STUDY; CROSS PRESENTATION; CYTOKINE PRODUCTION; DENDRITIC CELL; DRUG EFFICACY; DRUG STRUCTURE; FEMALE; HUMAN; HUMAN CELL; IMMUNIZATION; IMMUNOGENICITY; IMMUNOTHERAPY; MOUSE; NONHUMAN; PEPTIDE SYNTHESIS; T LYMPHOCYTE ACTIVATION; TUMOR IMMUNITY; TUMOR REGRESSION; ANIMAL; ANTIBODY SPECIFICITY; B LYMPHOCYTE; BIOSYNTHESIS; CHEMISTRY; CYTOLOGY; CYTOPLASM; IMMUNOLOGY; METABOLISM; NEOPLASM; STEREOISOMERISM; T LYMPHOCYTE; TIME; TRANSPORT AT THE CELLULAR LEVEL; TUMOR CELL LINE;

MUS;

ANIMALS; ANTIBODY SPECIFICITY; ANTIGENS, CD4; ANTIGENS, CD8; B-LYMPHOCYTES; BIOLOGICAL TRANSPORT; CELL LINE, TUMOR; CROSS-PRIMING; CYTOPLASM; DENDRITIC CELLS; EPITOPES, B-LYMPHOCYTE; FEMALE; GLYCOPROTEINS; HUMANS; IMMUNIZATION; IMMUNOGLOBULIN G; INTERFERON-GAMMA; LIPOPEPTIDES; MICE; NEOPLASMS; RECEPTOR, ERBB-2; STEREOISOMERISM; T-LYMPHOCYTES; TIME FACTORS; TOLL-LIKE RECEPTOR 2; VACCINES, SUBUNIT;

EID: 77955300116     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0011216     Document Type: Article

References (106)

1. Chentoufi AA, Nesburn AB, BenMohamed L (2009) Recent advances in multivalent self adjuvanting glycolipopeptide vaccine strategies against breast cancer. Arch Immunol Ther Exp (Warsz) 57: 409-423.
2. Bay S, Lo-Man R, Osinaga E, Nakada H, Leclerc C, et al. (1997) Preparation of a multiple antigen glycopeptide (MAG) carrying the Tn antigen. A possible approach to a synthetic carbohydrate vaccine. J Pept Res 49: 620-625.
3. Ingale S, Wolfert MA, Gaekwad J, Buskas T, Boons GJ (2007) Robust immune responses elicited by a fully synthetic three-component vaccine. Nat Chem Biol 3: 663-667.
4. Buskas T, Ingale S, Boons GJ (2005) Towards a fully synthetic carbohydrate-based anticancer vaccine: synthesis and immunological evaluation of a lipidated glycopeptide containing the tumor-associated tn antigen. Angew Chem Int Ed Engl 44: 5985-5988.
5. Lo-Man R, Vichier-Guerre S, Perraut R, Deriaud E, Huteau V, et al. (2004) A fully synthetic therapeutic vaccine candidate targeting carcinoma-associated Tn carbohydrate antigen induces tumor-specific antibodies in nonhuman primates. Cancer Res 64: 4987-4994.
6. Vichier-Guerre S, Lo-Man R, BenMohamed L, Deriaud E, Kovats S, et al. (2003) Induction of carbohydrate-specific antibodies in HLA-DR transgenic mice by a synthetic glycopeptide: a potential anti cancer vaccine for human use. J Pept Res 62: 117-124.
7. Shepherd C, Puzanov I, Sosman JA (2010) B-RAF inhibitors: an evolving role in the therapy of malignant melanoma. Curr Oncol Rep 12: 146-152.
8. Jackson DC, Lau YF, Le T, Suhrbier A, Deliyannis G, et al. (2004) A totally synthetic vaccine of generic structure that targets Toll-like receptor 2 on dendritic cells and promotes antibody or cytotoxic T cell responses. Proc Natl Acad Sci U S A 101: 15440-15445.
9. BenMohamed L, Wechsler SL, Nesburn AB (2002) Lipopeptide vaccines-yesterday, today, and tomorrow. Lancet Infect Dis 2: 425-431.
10. Weiner LM, Surana R, Wang S (2010) Monoclonal antibodies: versatile platforms for cancer immunotherapy. Nat Rev Immunol 10: 317-327.
11. Lee MKt, Sharma A, Czerniecki BJ (2010) It's all in for the HER family in tumorigenesis. Expert Rev Vaccines 9: 29-34.
12. Xiang SD, Scalzo-Inguanti K, Minigo G, Park A, Hardy CL, et al. (2008) Promising particle-based vaccines in cancer therapy. Expert Rev Vaccines 7: 1103-1119.
13. BenMohamed L, Gras-Masse H, Tartar A, Daubersies P, Brahimi K, et al. (1997) Lipopeptide immunization without adjuvant induces potent and long-lasting B, T helper, and cytotoxic T lymphocyte responses against a malaria liver stage antigen in mice and chimpanzees. Eur J Immunol 27: 1242-1253.
14. BenMohamed L, Krishnan R, Auge C, Primus JF, Diamond DJ (2002) Intranasal administration of a synthetic lipopeptide without adjuvant induces systemic immune responses. Immunology 106: 113-121.
15. BenMohamed L, Krishnan R, Longmate J, Auge C, Low L, et al. (2000) Induction of CTL response by a minimal epitope vaccine in HLA A*0201/DR1 transgenic mice: dependence on HLA class II restricted T(H) response. Hum Immunol 61: 764-779.
16. BenMohamed L, Thomas A, Bossus M, Brahimi K, Wubben J, et al. (2000) High immunogenicity in chimpanzees of peptides and lipopeptides derived from four new Plasmodium falciparum pre-erythrocytic molecules. Vaccine 18: 2843-2855.
17. BenMohamed L, Thomas A, Druilhe P (2004) Long-term multiepitopic cytotoxic-T-lymphocyte responses induced in chimpanzees by combinations of Plasmodium falciparum liver-stage peptides and lipopeptides. Infect Immun 72: 4376-4384.
18. Bourgeois C, Tanchot C (2003) Mini-review CD4 T cells are required for CD8 T cell memory generation. Eur J Immunol 33: 3225-3231.
19. Keding SJ, Danishefsky SJ (2004) Prospects for total synthesis: a vision for a totally synthetic vaccine targeting epithelial tumors. Proc Natl Acad Sci U S A 101: 11937-11942.
20. Kudryashov V, Glunz PW, Williams LJ, Hintermann S, Danishefsky SJ, et al. (2001) Toward optimized carbohydrate-based anticancer vaccines: epitope clustering, carrier structure, and adjuvant all influence antibody responses to Lewis(y) conjugates in mice. Proc Natl Acad Sci U S A 98: 3264-3269.
21. Renaudet O, BenMohamed L, Dasgupta G, Bettahi I, Dumy P (2008) Towards a Self-Adjuvanting Multivalent B and T cell Epitope Containing Synthetic Glycolipopeptide Cancer Vaccine. ChemMedChem 2: 425-431.
22. Monzavi-Karbassi B, Cunto-Amesty G, Luo P, Shamloo S, Blaszcyk-Thurin M, et al. (2001) Immunization with a carbohydrate mimicking peptide augments tumor-specific cellular responses. Int Immunol 13: 1361-1371.
23. Zhang X, Chentoufi AA, Dasgupta G, Nesburn AB, Wu M, et al. (2009) A genital tract peptide epitope vaccine targeting TLR-2 efficiently induces local and systemic CD8+ T cells and protects against herpes simplex virus type 2 challenge. Mucosal Immunol 2: 129-143.
24. Bettahi I, Dasgupta G, Renaudet O, Chentoufi AA, Zhang X, et al. (2009) Antitumor activity of a self-adjuvanting glyco-lipopeptide vaccine bearing B cell, CD4+ and CD8+ T cell epitopes. Cancer Immunol Immunother 58: 187-200.
25. Deliyannis G, Jackson DC, Ede NJ, Zeng W, Hourdakis I, et al. (2002) Induction of long-term memory CD8(+) T cells for recall of viral clearing responses against influenza virus. J Virol 76: 4212-4221.
26. Hosmalin A, Andrieu M, Loing E, Desoutter JF, Hanau D, et al. (2001) Lipopeptide presentation pathway in dendritic cells. Immunol Lett 79: 97-100.
27. Andrieu M, Desoutter JF, Loing E, Gaston J, Hanau D, et al. (2003) Two human immunodeficiency virus vaccinal lipopeptides follow different cross-presentation pathways in human dendritic cells. J Virol 77: 1564-1570.
28. Hoeffel G, Ripoche AC, Matheoud D, Nascimbeni M, Escriou N, et al. (2007) Antigen Crosspresentation by Human Plasmacytoid Dendritic Cells. Immunity.
29. Grigalevicius S, Chierici S, Renaudet O, Lo-Man R, Deriaud E, et al. (2005) Chemoselective assembly and immunological evaluation of multiepitopic glycoconjugates bearing clustered Tn antigen as synthetic anticancer vaccines. Bioconjug Chem 16: 1149-1159.
30. Monu N, Trombetta ES (2007) Cross-talk between the endocytic pathway and the endoplasmic reticulum in cross-presentation by MHC class I molecules. Curr Opin Immunol 19: 66-72.
31. Ackerman AL, Cresswell P (2004) Cellular mechanisms governing cross-presentation of exogenous antigens. Nat Immunol 5: 678-684.
32. van der Bruggen P, Van den Eynde BJ (2006) Processing and presentation of tumor antigens and vaccination strategies. Curr Opin Immunol 18: 98-104.
33. Groothuis TA, Neefjes J (2005) The many roads to cross-presentation. J Exp Med 202: 1313-1318.
34. Roy KC, Maricic I, Khurana A, Smith TR, Halder RC, et al. (2008) Involvement of secretory and endosomal compartments in presentation of an exogenous self-glycolipid to type II NKT cells. J Immunol 180: 2942-2950.
35. Samanta S, Sistla R, Chaudhuri A The use of RGDGWK-lipopeptide to selectively deliver genes to mouse tumor vasculature and its complexation with p53 to inhibit tumor growth. Biomaterials 31: 1787-1797.
36. Zhu Q, Egelston C, Gagnon S, Sui Y, Belyakov IM, et al. Using 3 TLR ligands as a combination adjuvant induces qualitative changes in T cell responses needed for antiviral protection in mice. J Clin Invest 120: 607-616.
37. Kang JY, Nan X, Jin MS, Youn SJ, Ryu YH, et al. (2009) Recognition of lipopeptide patterns by Toll-like receptor 2-Toll-like receptor 6 heterodimer. Immunity 31: 873-884.
38. Ruby CE, Weinberg AD (2009) The effect of aging on OX40 agonist-mediated cancer immunotherapy. Cancer Immunol Immunother 58: 1941-1947.
39. Qi X, Chu Z, Mahller YY, Stringer KF, Witte DP, et al. (2009) Cancer-selective targeting and cytotoxicity by liposomal-coupled lysosomal saposin C protein. Clin Cancer Res 15: 5840-5851.
40. Dorfel D, Appel S, Grunebach F, Weck MM, Muller MR, et al. (2005) Processing and presentation of HLA class I and II epitopes by dendritic cells after transfection with in vitro-transcribed MUC1 RNA. Blood 105: 3199-3205.
41. Pfender NA, Grosch S, Roussel G, Koch M, Trifilieff E, et al. (2008) Route of uptake of palmitoylated encephalitogenic peptides of myelin proteolipid protein by antigen-presenting cells: importance of the type of bond between lipid chain and peptide and relevance to autoimmunity. J Immunol 180: 1398-1404.
42. Khan KN, Kitajima M, Hiraki K, Fujishita A, Sekine I, et al. (2009) Toll-like receptors in innate immunity: role of bacterial endotoxin and toll-like receptor 4 in endometrium and endometriosis. Gynecol Obstet Invest 68: 40-52.
43. Khan S, Weterings JJ, Britten CM, de Jong AR, Graafland D, et al. (2009) Chirality of TLR-2 ligand Pam3CysSK4 in fully synthetic peptide conjugates critically influences the induction of specific CD8+ T-cells. Mol Immunol 46: 1084-1091.
44. Spohn R, Buwitt-Beckmann U, Brock R, Jung G, Ulmer AJ, et al. (2004) Synthetic lipopeptide adjuvants and Toll-like receptor 2-structure-activity relationships. Vaccine 22: 2494-2499.
45. Nava-Parada P, Forni G, Knutson KL, Pease LR, Celis E (2007) Peptide vaccine given with a Toll-like receptor agonist is effective for the treatment and prevention of spontaneous breast tumors. Cancer Res 67: 1326-1334.
46. Triantafilou M, Manukyan M, Mackie A, Morath S, Hartung T, et al. (2004) Lipoteichoic acid and toll-like receptor 2 internalization and targeting to the Golgi are lipid raft-dependent. J Biol Chem 279: 40882-40889.
47. Moron VG, Rueda P, Sedlik C, Leclerc C (2003) In vivo, dendritic cells can cross-present virus-like particles using an endosome-to-cytosol pathway. J Immunol 171: 2242-2250.
48. Fehr T, Haspot F, Mollov J, Chittenden M, Hogan T, et al. (2008) Alloreactive CD8 T cell tolerance requires recipient B cells, dendritic cells, and MHC class II. J Immunol 181: 165-173.
49. Dhodapkar MV, Krasovsky J, Steinman RM, Bhardwaj N (2000) Mature dendritic cells boost functionally superior CD8(+) T-cell in humans without foreign helper epitopes. J Clin Invest 105: R9-R14.
50. Hearn AR, de Haan L, Pemberton AJ, Hirst TR, Rivett AJ (2004) Trafficking of exogenous peptides into proteasome-dependent major histocompatibility complex class I pathway following enterotoxin B subunit-mediated delivery. J Biol Chem 279: 51315-51322.
51. Radhakrishnan S, Cabrera R, Bruns KM, Van Keulen VP, Hansen MJ, et al. (2010) Retraction: Indirect recruitment of a CD40 signaling pathway in dendritic cells by B7-DC cross-linking antibody modulates T cell functions. PLoS One 5.
52. Watchmaker PB, Berk E, Muthuswamy R, Mailliard RB, Urban JA, et al. (2010) Independent regulation of chemokine responsiveness and cytolytic function versus CD8+ T cell expansion by dendritic cells. J Immunol 184: 591-597.
53. Belz GT, Carbone FR, Heath WR (2002) Cross-presentation of antigens by dendritic cells. Crit Rev Immunol 22: 439-448.
54. Larsson M, Fonteneau JF, Bhardwaj N (2001) Dendritic cells resurrect antigens from dead cells. Trends Immunol 22: 141-148.
55. Hotta C, Fujimaki H, Yoshinari M, Nakazawa M, Minami M (2006) The delivery of an antigen from the endocytic compartment into the cytosol for cross-presentation is restricted to early immature dendritic cells. Immunology 117: 97-107.
56. Rock KL, Shen L (2005) Cross-presentation: underlying mechanisms and role in immune surveillance. Immunol Rev 207: 166-183.
57. Belizaire R, Unanue ER (2009) Targeting proteins to distinct subcellular compartments reveals unique requirements for MHC class I and II presentation. Proc Natl Acad Sci U S A 106: 17463-17468.
58. Smith TR, Tang X, Maricic I, Garcia Z, Fanchiang S, et al. (2009) Dendritic cells use endocytic pathway for cross-priming class Ib MHC-restricted CD8alphaalpha+TCRalphabeta+ T cells with regulatory properties. J Immunol 182: 6959-6968.
59. Chen L, Jondal M (2004) Alternative processing for MHC class I presentation by immature and CpG-activated dendritic cells. Eur J Immunol 34: 952-960.
60. Svensson M, Wick MJ (1999) Classical MHC class I peptide presentation of a bacterial fusion protein by bone marrow-derived dendritic cells. Eur J Immunol 29: 180-188.
61. Hakomori S (2001) Tumor-associated carbohydrate antigens defining tumor malignancy: basis for development of anti-cancer vaccines. Adv Exp Med Biol 491: 369-402.
62. Syrigos KN, Karayiannakis AJ, Zbar A (1999) Mucins as immunogenic targets in cancer. Anticancer Res 19: 5239-5244.
63. Zhang X, Issagholian A, Berg EA, Fishman JB, Nesburn AB, et al. (2005) Th-cytotoxic T-lymphocyte chimeric epitopes extended by Nepsilon-palmitoyl lysines induce herpes simplex virus type 1-specific effector CD8+ Tc1 responses and protect against ocular infection. J Virol 79: 15289-15301.
64. Springer GF (1997) Immunoreactive T and Tn epitopes in cancer diagnosis, prognosis, and immunotherapy. J Mol Med 75: 594-602.
65. Tarp MA, Clausen H (2008) Mucin-type O-glycosylation and its potential use in drug and vaccine development. Biochim Biophys Acta 1780: 546-563.
66. Sorensen AL, Reis CA, Tarp MA, Mandel U, Ramachandran K, et al. (2006) Chemoenzymatically synthesized multimeric Tn/STn MUC1 glycopeptides elicit cancer-specific anti-MUC1 antibody responses and override tolerance. Glycobiology 16: 96-107.
67. Curigliano G, Spitaleri G, Pietri E, Rescigno M, de Braud F, et al. (2006) Breast cancer vaccines: a clinical reality or fairy tale? Ann Oncol 17: 750-762.
68. Sorensen AL, Reis CA, Tarp MA, Mandel U, Ramachandran K, et al. (2005) Chemoenzymatically synthesized multimeric Tn/STn MUC1 glycopeptides elicit cancer specific anti-MUC1 antibody responses and override tolerance. Glycobiology.
69. Slovin SF, Keding SJ, Ragupathi G (2005) Carbohydrate vaccines as immunotherapy for cancer. Immunol Cell Biol 83: 418-428.
70. Curigliano G, Spitaleri G, Pietri E, Rescigno M, de Braud F, et al. (2005) Breast cancer vaccines: a clinical reality or fairy tale? Ann Oncol.
71. Vazquez-Martin C, Cuevas E, Gil-Martin E, Fernandez-Briera A (2004) Correlation analysis between tumor-associated antigen sialyl-Tn expression and ST6GalNAc I activity in human colon adenocarcinoma. Oncology 67: 159-165.
72. Manimala JC, Li Z, Jain A, VedBrat S, Gildersleeve JC (2005) Carbohydrate array analysis of anti-Tn antibodies and lectins reveals unexpected specificities: implications for diagnostic and vaccine development. Chembiochem 6: 2229-2241.
73. Hollenbaugh JA, Dutton RW (2006) IFN-gamma regulates donor CD8 T cell expansion, migration, and leads to apoptosis of cells of a solid tumor. J Immunol 177: 3004-3011.
74. Borsutzky S, Kretschmer K, Becker PD, Muhlradt PF, Kirschning CJ, et al. (2005) The mucosal adjuvant macrophage-activating lipopeptide-2 directly stimulates B lymphocytes via the TLR2 without the need of accessory cells. J Immunol 174: 6308-6313.
75. Ingale S, Wolfert MA, Buskas T, Boons GJ (2009) Increasing the antigenicity of synthetic tumor-associated carbohydrate antigens by targeting Toll-like receptors. Chembiochem 10: 455-463.
76. Peeters CC, Tenbergen-Meekes AM, Poolman JT, Beurret M, Zegers BJ, et al. (1991) Effect of carrier priming on immunogenicity of saccharide-protein conjugate vaccines. Infect Immun 59: 3504-3510.
77. Bettahi I, Nesburn AB, Yoon S, Zhang X, Mohebbi A, et al. (2007) Protective Immunity against Ocular Herpes Infection and Disease Induced by Highly Immunogenic Self-Adjuvanting Glycoprotein D Lipopeptide Vaccines. Invest Ophthalmol Vis Sci 48: 4643-4653.
78. Margalit A, Sheikhet HM, Carmi Y, Berko D, Tzehoval E, et al. (2006) Induction of antitumor immunity by CTL epitopes genetically linked to membrane-anchored beta2-microglobulin. J Immunol 176: 217-224.
79. Bettahi I, Zhang X, Afifi RE, BenMohamed L (2006) Protective Immunity to Genital Herpes Simplex Virus Type 1 and Type 2 Provided by Self-Adjuvanting Lipopeptides That Drive Dendritic Cell Maturation and Elicit a Polarized Th1 Immune Response. Viral Immunology 19: 220-236.
80. Dasgupta G, Nesburn AB, Wechsler SL, Benmohamed L (2010) Developing an asymptomatic mucosal herpes vaccine: the present and the future. Future Microbiol 5: 1-4.
81. Chentoufi AA, Dasgupta G, Nesburn AB, Bettahi I, Binder NR, et al. (2010) Nasolacrimal Duct Closure Modulates Ocular Mucosal and Systemic CD4+ T-Cell Responses Induced following Topical Ocular or Intranasal Immunization. Clin Vaccine Immunol 17: 342-353.
82. Chentoufi AA, Dasgupta G, Christensen ND, Hu J, Choudhury ZS, et al. (2010) A novel HLA (HLA-A*0201) transgenic rabbit model for preclinical evaluation of human CD8+ T cell epitope-based vaccines against ocular herpes. J Immunol 184: 2561-2571.
83. Norell H, Zhang Y, McCracken J, Martins da Palma T, Lesher A, et al. (2010) CD34-based enrichment of genetically engineered human T cells for clinical use results in dramatically enhanced tumor targeting. Cancer Immunol Immunother 59: 851-862.
84. Vicente-Suarez I, Brayer J, Villagra A, Cheng F, Sotomayor EM (2009) TLR5 ligation by flagellin converts tolerogenic dendritic cells into activating antigen-presenting cells that preferentially induce T-helper 1 responses. Immunol Lett 125: 114-118.
85. Zhu X, Ramos TV, Gras-Masse H, Kaplan BE, BenMohamed L (2004) Lipopeptide Epitopes Extended by Ne-Palmitoyl Lysine Moiety Increases Uptake and Maturation of Dendritic Cell Through a Toll-Like Receptor 2 Pathway and Triggers a Th1-Dependent Protective Immunity. Eur J Immunol 34: 1142-1149.
86. Heath WR, Belz GT, Behrens GM, Smith CM, Forehan SP, et al. (2004) Cross-presentation, dendritic cell subsets, and the generation of immunity to cellular antigens. Immunol Rev 199: 9-26.
87. Schnorrer P, Behrens GM, Wilson NS, Pooley JL, Smith CM, et al. (2006) The dominant role of CD8+ dendritic cells in cross-presentation is not dictated by antigen capture. Proc Natl Acad Sci U S A 103: 10729-10734.
88. Tseng JC, Zanzonico PB, Levin B, Finn R, Larson SM, et al. (2006) Tumor-specific in vivo transfection with HSV-1 thymidine kinase gene using a Sindbis viral vector as a basis for prodrug ganciclovir activation and PET. J Nucl Med 47: 1136-1143.
89. Belnoue E, Guettier C, Kayibanda M, Le Rond S, Crain-Denoyelle AM, et al. (2004) Regression of established liver tumor induced by monoepitopic peptide-based immunotherapy. J Immunol 173: 4882-4888.
90. Lubaroff DM, Karan D (2009) CpG oligonucleotide as an adjuvant for the treatment of prostate cancer. Adv Drug Deliv Rev 61: 268-274.
91. Lazoura E, Apostolopoulos V (2005) Rational Peptide-based vaccine design for cancer immunotherapeutic applications. Curr Med Chem 12: 629-639.
92. Mesa C, Fernandez LE (2004) Challenges facing adjuvants for cancer immunotherapy. Immunol Cell Biol 82: 644-650.
93. Petrovsky N, Aguilar JC (2004) Vaccine adjuvants: current state and future trends. Immunol Cell Biol 82: 488-496.
94. Maraskovsky E, Sjolander S, Drane DP, Schnurr M, Le TT, et al. (2004) NY-ESO-1 protein formulated in ISCOMATRIX adjuvant is a potent anticancer vaccine inducing both humoral and CD8+ t-cell-mediated immunity and protection against NY-ESO-1+ tumors. Clin Cancer Res 10: 2879-2890.
95. Warger T, Schild H, Rechtsteiner G (2007) Initiation of adaptive immune responses by transcutaneous immunization. Immunol Lett 109: 13-20.
96. Casillas S, Pelley RJ, Milsom JW (1997) Adjuvant therapy for colorectal cancer: present and future perspectives. Dis Colon Rectum 40: 977-992.
97. Moron G, Dadaglio G, Leclerc C (2004) New tools for antigen delivery to the MHC class I pathway. Trends Immunol 25: 92-97.
98. Davila E, Kennedy R, Celis E (2003) Generation of antitumor immunity by cytotoxic T lymphocyte epitope peptide vaccination, CpG-oligodeoxynucleotide adjuvant, and CTLA-4 blockade. Cancer Res 63: 3281-3288.
99. Nesburn AB, Bettahi I, Zhang X, Zhu X, Chamberlain W, et al. (2006) Topical/mucosal delivery of sub-unit vaccines that stimulate the ocular mucosal immune system. Ocul Surf 4: 178-187.
100. BenMohamed L, Belkaid Y, Loing E, Brahimi K, Gras-Masse H, et al. (2002) Systemic immune responses induced by mucosal administration of lipopeptides without adjuvant. Eur J Immunol 32: 2274-2281.
101. Gahery H, Daniel N, Charmeteau B, Ourth L, Jackson A, et al. (2006) New CD4+ and CD8+ T cell responses induced in chronically HIV type-1-infected patients after immunizations with an HIV type 1 lipopeptide vaccine. AIDS Res Hum Retroviruses 22: 684-694.
102. Durier C, Launay O, Meiffredy V, Saidi Y, Salmon D, et al. (2006) Clinical safety of HIV lipopeptides used as vaccines in healthy volunteers and HIV-infected adults. Aids 20: 1039-1049.
103. Gahery H, Choppin J, Bourgault I, Fischer E, Maillere B, et al. (2005) HIV preventive vaccine research at the ANRS: the lipopeptide vaccine approach. Therapie 60: 243-248.
104. Roth A, Rohrbach F, Weth R, Frisch B, Schuber F, et al. (2005) Induction of effective and antigen-specific antitumour immunity by a liposomal ErbB2/HER2 peptide-based vaccination construct. Br J Cancer 92: 1421-1429.
105. Vichier-Guerre S, Lo-Man R, Huteau V, Deriaud E, Leclerc C, et al. (2004) Synthesis and immunological evaluation of an antitumor neoglycopeptide vaccine bearing a novel homoserine Tn antigen. Bioorg Med Chem Lett 14: 3567-3570.
106. Ercolini AM, Ladle BH, Manning EA, Pfannenstiel LW, Armstrong TD, et al. (2005) Recruitment of latent pools of high-avidity CD8(+) T cells to the antitumor immune response. J Exp Med 201: 1591-1602.